Recent Updates
Recently added Catalysts

Fibrin Sealant, ARTISS /ml VH SD

Phase 3

Deep Partial or Full Thickness Wounds | Monoclonal antibody | Other |Baxter International Inc.|Last Updated: Apr 20, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment150
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00157131Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn PatientsPHASE3 COMPLETED 150Jun 1, 2004Feb 1, 2007Apr 20, 201717 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Complete wound closure by Day 28 after treatment with either FS 4IU VH S/D or staples as determined by a blinded independent review of the Day 28 photographs
28 days after treatment
Adverse experiences (AEs) deemed possibly or probably related to treatment with FS 4IU VH S/D
12 months after treatment
Secondary Endpoints
Presence of hematoma/seroma on Day 1
1 day after treatment
Percent area of hematoma/seroma on Day 1
1 day after treatment
100% engraftment by Day 5
5 days after treatment
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
FS 4IU VH S/DEXPERIMENTALFS 4IU VH S/D was administered intraoperatively to the wound bed by spray application using the TISSOMAT and Spray Set. Only the DUPLOJECTvii system and Spray Set (connection tube with sterile filter and spray head) device was used for simultaneous spray application of the study product. A thin layer of FS 4IU VH S/D was applied to the wound bed using a "painting motion" from side to side to achieve coverage. The recommended dosing volume was 2.0 to 4.0 mL/100 cm2. One 2-mL pack (4 mL total volume) of FS 4IU VH S/D applied using the TISSOMAT and Spray Set was sufficient to coat a wound bed of 100-200 cm2.
StaplesACTIVE_COMPARATORStaples are the current standard of care in burn surgery and are well accepted as the control in this type of study.
Interventions
NameTypeDescription
Fibrin Sealant, ARTISS 4IU/ml VH SDBIOLOGICALFS 4IU VH S/D, a two-component fibrin sealant with 4 IU/mL human thrombin, vapor heated, solvent detergent treated, provided in a frozen, ready-to-use formulation. Administration by a topical spray application using the TISSOMAT device and Spray Set.
StaplesOTHERAdministration by mechanical/multiple point fixation.
Unlock Study Design Details
Eligibility Criteria
Age RangeN/A — 65 Years
SexALL
Healthy VolunteersNo
Study Sites17

Inclusion Criteria: * Subjects or their legal representatives, who have read, understood and signed a written informed consent. * Subjects of either sex. * Female subjects of childbearing potential with a negative urine or serum pregnancy test on admission. * Subjects who are \<= 65 years of age in...

Countries:United States
Unlock Eligibility Criteria